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Summary A prospective randomised multicentre clinical study was undertaken for 2 years and 3 months
from November 1982, with the aim of examining the significance of using a combination of ftorafur (FT) and
tamoxifen (TAM) for post-operative adjuvant therapy of breast cancer. Patients had either stage II or stage
Illa disease, were age 75 or below and had undergone radical mastectomy. Patients were divided into two
groups and received one of the following treatment protocols: treatment A, intravenous administration of
doxorubicin (DOX), 20mg on the day of surgery and 10mg the next day, followed by oral FT 50mg day-'
for 2 years from the 14th day; treatment B, the same pattern of DOX administration for the first 2 days,
followed by a combined therapy of FT and TAM 20 mg day-' for 2 years. The number of patients was 546
(treatment A 274 and treatment B 272), of whom 34 (6%) were ineligible. The remaining 512 patients
(treatment A 254 and treatment B 258) were followed up for 5 years for analysis. Significantly higher 5 year
disease-free rate and 5 year survival rates were observed with treatment B compared with treatment A. When
seen in terms of background factors, node-positive patients appeared to derive more benefit from tamoxifen
than node-negative patients, but the oestrogen receptor-negative and premenopausal subgroups appeared to
derive about the same benefit as those who were oestrogen receptor positive and post-menopausal. Indeed,
survival in the premenopausal group was significantly better with tamoxifen (P = 0.04). No increase in
side-effects was seen by combining TAM with FT. The study results demonstrate that concomitant administra-
tion of FT and TAM is better than FT alone for post-operative adjuvant therapy for breast cancer.
Tamoxifen (TAM), when used as an adjuvant therapy in
primary breast cancer, has been shown to improve survival
and disease-free survival (DFS). Compared with no treatment
tamoxifen 20 mg day-' for 2 years (Nolvadex Adjuvant Trial
Organization, 1988) and compared with no post-operative
treatment tamoxifen 20 mg day-' for 5 years (starting at the
time of first relapse) (MRC Scottish Cancer Trials Office,
1987) is beneficial. More recently, the Early Breast Cancer
Trialists' Collaborative Group (1992) Overview has con-
firmed the benefit of adjuvant TAM therapy.
Ftorafur (FT) is an analogue of 5-fluorouracil (5-FU)
widely used in Japan for treatment of stomach and colon
cancers. The positive effects of adding TAM to FT in recur-
rent breast cancer (in which response rates to FT alone
ranged between 20 and 30%) have been reported previously
(Wada et al., 1981). We started a multicentre, randomised,
prospective trial in November 1982 for the purpose of study-
ing the value of TAM in combination with FT in patients
who had undergone surgery for stage II or IIIa breast cancer.
This study, in the Hokkaido region, was conducted in col-
laboration with workers in six other Japanese regions, who
also assessed the value ofadding tamoxifen to chemotherapy,
and thus forms part of the adjuvant chemo-endocrine
therapy for breast cancer 1 (ACETBC-1) study. The present
paper reports that, in Hokkaido, significant improvements in
5 year survival and 5 year disease-free survival were achieved
by adding TAM to FT.
Materials and methods
This study included female patients, aged <75 years, who
had undergone a radical mastectomy for stage II or IIIa
(according to the new TNM classification based on Interna-
tional Union Against Cancer criteria established in 1978)
Correspondence: J. Uchino, First Department of Surgery, Hokkaido
University School of Medicine, N-15 W-7, Kita-ku, Sapporo, 060
Japan.
*See the Appendix.
Received 20 May 1993; and in revised form 23 November 1993.
invasive primary breast cancer. Women with any of the
following characteristics were considered ineligible for this
trial: previous treatment of cancer, post-operative radio-
therapy, surgical endocrine manipulations such as oophorec-
tomy or preoperative leucocyte counts <3,000mm-3,
platelet counts < 100,000 mm- or total protein <6.0 g dl-'.
Patients with bilateral breast cancer, inflammatory breast
cancer or who were pregnant or nursing, or those with
concomitant malignancy, were excluded.
The eligible patients (stage II or IIIa breast cancer) were
randomised to receive either treatment A or treatment B
using the envelope method. Treatment A: DOX was given
intravenously at the dose 20 mg immediately after operation
and at 10 mg the following day, and 2 years of FT
monotherapy (600 mg day-', p.o.) was started 14 days after
surgery. Treatment B: DOX was given as in group A. A 2
year oral combination therapy including 600 mgday-' FT
and 20 mg day-' TAM was started 14 days after surgery
(Figure 1).
Of the 546 patients randomised during a period of 2 years
and 2 months from November 1982 to January 1985, 34
(6.2%) were excluded from statistical analyses for the follow-
ing reasons: inappropriate stage in 15 patients, non-invasive
cancer in 11, previous cancer treatment in three, age over 75
years in two, and TIS, bilateral breast cancer and con-
comitant malignancy in one each. Consequently the follow-
up included 512 eligible patients (Table I).
Oestrogen receptor (ER) status was measured by the
dextran-coated charcoal (DCC) method at Mitsubishi Yuka
Biomedical Laboratories, Tokyo, and tumours containing
more than 3 fmol mg-' protein were considered positive.
Chi-square tests or Mann-Whitney U-tests were used for
between-group comparison of background factors. The Kap-
lan-Meier method for calculations of overall survival (OS)
and DFS rates and the log-rank test for significance tests of
differences in the OS and DFS rates were used.
Results
The two groups were similar in terms of age, menopausal
status, type of operation, histological type and ER status. An
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Figure 1 Protocol design (period of entry November 1982 to January 1985).
Table I Number of patients and reasons ofineligible patients
A B
No. of ineligible patients 20 (7%) 14 (5%) 34 (6%)
Non-invasive cancer 6 5 11
TIS I 0 1
Bilateral breast cancer 1 0 1
Concomitant malignancy 1 0 1
Inappropriate stages 7 8 15
Over 76 years of age 2 0 2
Previous cancer treatment 2 1 3
No. of eligible patients 254 258 512
No. of total patients 274 272 546
Table II Background factors of eligible patients
A B
(n = 254) (n = 258) X2-test
Age
Median 48 49
Range 28-75 26-75
Menopausal status
Pre 133 142 P= 0.60
Post 121 116
Operation
Modified 31 38 P= 0.17
Standard 190 199
Extend 33 21
Nodal status
0 109 140 P= 0.083
1-3 80 67
>4 65 51
Histology
Invasive 245 243 P = 0.45
Special types 9 14
Unknown 0 1
ER status
Positive 116 120 P = 0.40
Negative 75 86
Unknown 63 52
Table IH Five year overall survival rate by factors
Factor Five year OS rate (%)
ER positive A 82.3 (P 040
B 91.5 (=.0
ER negative A 72.3 (P= 0.24)
B 80.8(P 0.4
Node negative A 93.5 (P=0.80)
B 92.7(P 0.)
Node positive A 71.2 (P = 0.018)
B 84.4(P018
Premenopausal A 78.7
B 88.4 (P = 0.038)
Post-menopausal A 83.3 (P= 0.18) B 89.4 (=.8
imbalance was observed only for nodal status: treatment
group A included fewer node-negative patients (P = 0.083 for
chi-square test and P = 0.013 for U-test) (Table II). The
median follow-up time in the 512 eligible patients was 60
months as of March 1990. The OS rate was significantly
increased by TAM, as evidenced by 5 year cumulative sur-
vival rates being 89% for patients receiving treatment B and
81% for those receiving treatment A (P = 0.016) (Figure 2).
When divided into subgroups, however, the effect was
significant in ER-positive, node-positive and premenopausal
subgroups, whereas in node-negative, post-menopausal or
ER-negative subgroups the clinical effect did not reach statis-
tical significance, although there was a trend in favour of
tamoxifen in the latter two subgroups (Table III).
The 5 year DFS rate was significantly higher in the treat-
ment B group than in the treatment A group (80.9% vs
69.2%, P = 0.0026) (Figure 3). Relapse occurred in 76 and 48
patients receiving treatments A and B respectively. The first
relapse in the local site occurred less frequently in patients on
treatment B than those on treatment A (Table IV). Inter-
group differences in 5 year DFS reached the conventional
level of statistical significance in node-positive, ER-positive
and post-menopausal subgroups. But again there was a non-
significant trend for better DFS survival with tamoxifen
among the premenopausal and the ER-negative subgroups of
tamoxifen (Table V).
We corrected for the between-group imbalance in nodal
status using Cox's proportional hazard model. Even after
these corrections, the difference in the corrected disease-free
survival curves remained statistically significant (P = 0.0074)
(Figure 4).
There was no difference between the groups in terms of
incidence ofchanges in leucocyte counts, impaired liver func-
tion, pigmentation, etc., suggesting no potentiation of
adverse effects by addition of TAM to FT (Table VI).
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Discussion
The largest trial investigating the addition of tamoxifen to
chemotherapy carried out on 1,858 breast cancer patients by
Fisher et al. (1987) reported that there was no improvement
in 5 year survival rates with the addition of 2 years of TAM
to L-phenylalanine mustard (L-PAM) and 5-FU. A significant
prolongation of recurrence-free survival was noted, however,
among the subgroup of post-menopausal patients with four
or more involved nodes and with ER-positive tumours.
Hubay et al. (1984) studied 311 patients with stage II
breast cancer treated with cyclophosphamide, methotrexate
and 5-FU (CMF) alone or combined with TAM (± BCG),
and again only a subgroup of patients with tumour 3 cm or
larger in size in addition to three of the factors from Fisher's
report showed improvement from the addition of TAM. The
Bordeaux group in the analysis of stage II and ER-positive
cancer patients treated with CMF plus TAM have also pos-
Figure 3 Overall DFS.
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Table IV Site of initial recurrence
A B
Soft tissues 45 17
Contralateral breast 2 4
Skin 9 4
Subcutis 16 6
Lymph nodes 24 7
Mediastinum and/or hilar 1 2
Miscellaneous 1 0
Bone 31 25
Viscera 20 20
Lung 10 12
Pleura 6 5
Pericardial fluid 1 0
Liver 7 5
Peritoneum 1 1
Brain 1 0
Miscellaneous I I
Miscellaneous 1 1
No. of patients with recurrence 76 48
Table V Five year DFS rate by factors
Factor Five year DFS rate (%)
ER positive A 66.1 (P = 0.029) B 83.1(P029
ER negative A 64.8 (P=0.38) B 70.5(P 0.8
Node negative A 86.8 (P = 0.85) B 86.8 ( .5
Node positive A 55.6 (P= 0.024) B 73.9(P=024
Premenopausal A 67.8 (P= 0.10) B 76.3 (P=0.0)
Post-menopausal A 70.9 ( .09 B 86.6 ( .09
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Figure 4 Adjusted overall survival (a) and DFS (b) by Cox's
hazard model. a, Treatment, P = 0.068 (B7A); menopausal status,
P=0.26; nodal status, P<0.0001; ER, P=0.0019 (+71); his-
tology, P = 0.47. b, Treatment, P =0.0074 (B7A); menopausal
status, P= 0.028 (pre>post); nodal status, P<0.0001; ER,
P= 0.091; histology, P= 0.059.
Table VI Side-effects
A B
Leucocyte count <3,000 31 (12.2%) 25 (9.7%)
Liver dysfunction 48 (18.9%) 40 (15.5%)
Pigmentation 17 (6.7%) 19 (7.4%)
Anorexia 72 (28.3%) 47 (18.5%)- 88 (34.1%) 67 (26.0%)a
Nausea and/or vomiting 37 (14.6%) 31 (12.2%)a 50 (19.4%) 43 (16.7%)-
General fatigue 56 (22.0%) 34 (13.4%)a 60 (25.6%) 49 (19.0%)a
aExcluding the patients with symptoms by DOX administration.
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tulated that there would be a greater advantage from TAM
in a group with tumours 3 cm or larger in size than those
with tumours less than 3 cm in size (Mauriac et al., 1988).
This study was performed as a part of nationwide Japanese
trials on post-operative adjuvant chemo-endocrine therapy
for stage II and stage IIIa breast cancer with ftorafur (FT)
alone and FT plus tamoxifen (TAM) and six districts. There
were some deviations from the protocol, in the stage and the
condition of patients, and in the chemotherapy given on the
first and second days after operation (doxorubicin 20 mg,
followed by DOX 10 mg in the Hokkaido district, or MMC
20 mg followed by 10 mg in the Tokyo district). However,
the schedules of FT and FT plus TAM were identical in all
districts. The overall results of the Japanese Cooperative
Study were as follows (Abe et al., 1992):
(1) Five year survival rates were 85.0% with FT alone
(n = 2,393) and 87.8% with FT plus TAM (n = 2,347) with a
difference of 2.8%. The difference was significant with
P = 0.0069.
(2) Five year disease-free survival rates were 76.0% with FT
alone and 81.3% with FT plus TAM with significant
difference (P<0.0001).
In our study, the combination of FT and TAM was also
shown to be significantly more effective than FT alone in
improving overall survival as well as recurrence-free survival.
The effects of adding TAM to FT were demonstrated even
after correction of the imbalance in node status. Although
the differences between chemotherapy regimens should be
considered, our data are consistent with the results of the
above trials in terms of the influence of ER status and nodal
status, but not menopausal status. Our study did show a
survival benefit from TAM in premenopausal patients in
contrast to these studies and the results of the Eastern
Cooperative Oncology Group (ECOG) and North Central
Cancer Treatment (NCCTG) Group's studies (Ingle et al.,
1989; Tormey et al., 1990), perhaps because these two studies
used just 1 year of tamoxifen.
In terms of the mechanism of anti-tumour activity, chemo-
therapy and TAM are fundamentally different. Chemo-
therapy is likely to be effective in proliferating cells, while
TAM has a cytostatic effect on tumour cells. It might be
expected, therefore, that concurrent use of chemotherapy and
tamoxifen would make chemotherapy with antimetabolites
such as ftorafur less effective. Also lower efficacy using TAM
in the presence of oestradiol in cultured cell experiments is
well known (Obsbourne et al., 1984). Although our data
provide no support, it may be that in premenopausal patients
the benefits of tamoxifen may be less because of higher levels
of circulating destroyers. Tamoxifen might also be more
effective in a sequential or intermittent treatment schedule
with chemotherapy and/or by prior reduction of oestradiol
levels - e.g. by ovarian ablation. These approaches are wor-
thy of further investigation.
From our study, we found the addition of 2 years ofTAM
to adjuvant FT therapy to be beneficial in pre- and post-
menopausal patients with stage II or IIIa breast cancer, and
that TAM did not increase the incidence of any adverse
effects.
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